---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-019775"
form_type: "8-K"
ticker: "MBOT"
cik: "0000883975"
company_name: "Microbot Medical Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:24:48.357702+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Microbot Medical appoints Alon Tamir VP Sales EMEA, targets CE mark by end of 2026

## Summary
- Alon Tamir named Vice President of Sales for Europe, Middle East and Asia (EMEA) to lead international expansion.
- Company expects CE mark approval by end of 2026; leveraging FDA clearance received September 2025.
- Europe has approximately 2.3 million peripheral endovascular procedures annually, comparable to U.S. market size.
- LIBERTY Endovascular Robotic System is in full market release in the U.S. after limited market release.

## SEC filing metadata
- accession: 0001493152-26-019775
- form_type: 8-K
- ticker: MBOT
- cik: 0000883975
- company_name: Microbot Medical Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/883975/000149315226019775/0001493152-26-019775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/883975/000149315226019775/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-019775
- JSON: https://secwatch.observer/filing/0001493152-26-019775.json
- Plain text: https://secwatch.observer/filing/0001493152-26-019775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.